These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

156 related articles for article (PubMed ID: 20455656)

  • 21. Regenerative medicine, resource and regulation: lessons learned from the remedi project.
    Ginty PJ; Rayment EA; Hourd P; Williams DJ
    Regen Med; 2011 Mar; 6(2):241-53. PubMed ID: 21391857
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Current and future state of FDA-CMS parallel reviews.
    Messner DA; Tunis SR
    Clin Pharmacol Ther; 2012 Mar; 91(3):383-5. PubMed ID: 22343814
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Industry perceptions of barriers to commercialization of regenerative medicine products in the UK.
    Plagnol AC; Rowley E; Martin P; Livesey F
    Regen Med; 2009 Jul; 4(4):549-59. PubMed ID: 19580404
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Financing home health-care products and services.
    Curtiss FR
    Am J Hosp Pharm; 1986 Jan; 43(1):121-31. PubMed ID: 3082192
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Developing drugs for developing countries.
    Ridley DB; Grabowski HG; Moe JL
    Health Aff (Millwood); 2006; 25(2):313-24. PubMed ID: 16522573
    [TBL] [Abstract][Full Text] [Related]  

  • 26. New US agent requirements.
    Donawa M
    Med Device Technol; 2002; 13(1):35-7. PubMed ID: 11921780
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Considerations for tissue-engineered and regenerative medicine product development prior to clinical trials in the United States.
    Lee MH; Arcidiacono JA; Bilek AM; Wille JJ; Hamill CA; Wonnacott KM; Wells MA; Oh SS
    Tissue Eng Part B Rev; 2010 Feb; 16(1):41-54. PubMed ID: 19728784
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The history and contemporary challenges of the US Food and Drug Administration.
    Borchers AT; Hagie F; Keen CL; Gershwin ME
    Clin Ther; 2007 Jan; 29(1):1-16. PubMed ID: 17379043
    [TBL] [Abstract][Full Text] [Related]  

  • 29. REIMBURSEMENT OF CELL-BASED REGENERATIVE THERAPY IN THE UK AND FRANCE.
    Mahalatchimy A
    Med Law Rev; 2016; 24(2):234-58. PubMed ID: 27083495
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Characteristics of orphan drug applications that fail to achieve marketing approval in the USA.
    Heemstra HE; Leufkens HG; Rodgers RP; Xu K; Voordouw BC; Braun MM
    Drug Discov Today; 2011 Jan; 16(1-2):73-80. PubMed ID: 21094692
    [TBL] [Abstract][Full Text] [Related]  

  • 31. A Review of the Regulatory Framework for Initiation and Acceleration of Patient Access to Innovative Medical Products in Japan.
    Matsushita S; Tachibana K; Nakai K; Sanada S; Kondoh M
    Clin Pharmacol Ther; 2019 Sep; 106(3):508-511. PubMed ID: 30883696
    [No Abstract]   [Full Text] [Related]  

  • 32. Recent developments in federal reimbursement for home health-care services and products.
    Curtiss FR
    Am J Hosp Pharm; 1988 Aug; 45(8):1682-90. PubMed ID: 3064589
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Authorization and reimbursement of orphan drugs in an international comparison].
    Roll K; Stargardt T; Schreyögg J
    Gesundheitswesen; 2011 Aug; 73(8-9):504-14. PubMed ID: 20848380
    [TBL] [Abstract][Full Text] [Related]  

  • 34. How Medicare could use comparative effectiveness research in deciding on new coverage and reimbursement.
    Pearson SD; Bach PB
    Health Aff (Millwood); 2010 Oct; 29(10):1796-804. PubMed ID: 20921478
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Advanced Tissue Sciences Inc.: learning from the past, a case study for regenerative medicine.
    Pangarkar N; Pharoah M; Nigam A; Hutmacher DW; Champ S
    Regen Med; 2010 Sep; 5(5):823-35. PubMed ID: 20868336
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Inclusion of cost effectiveness in licensing requirements of new drugs: the fourth hurdle.
    Taylor RS; Drummond MF; Salkeld G; Sullivan SD
    BMJ; 2004 Oct; 329(7472):972-5. PubMed ID: 15499118
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Import for export; reporting and recordkeeping requirements for unapproved or violative products imported for further processing or incorporation and subsequent export--FDA. Proposed rule.
    Fed Regist; 1998 Nov; 63(226):64930-7. PubMed ID: 10338872
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Conditional approval: Japan lowers the bar for regenerative medicine products.
    Sipp D
    Cell Stem Cell; 2015 Apr; 16(4):353-6. PubMed ID: 25842975
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Balancing US patent and FDA approval processes: strategically optimizing market exclusivity.
    Fernandez DS; Huie JT
    Drug Discov Today; 2004 Jun; 9(12):509-12. PubMed ID: 15183155
    [No Abstract]   [Full Text] [Related]  

  • 40. Should you let the FDA decide what drugs you pay for?
    Dutton G
    Bus Health; 1996 Oct; 14(10):65, 69-70, 73. PubMed ID: 10161492
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.